drugset
drugset / Trial / NCT03226444

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

NCT03226444 ↗

Phase 1/2 Completed 204 enrolled TearSolutions, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome

Timeline

Start
2017-06-30
Primary completion
2019-12-27
Completion
2019-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacripep Unknown 0.005 % Topical
Subject Lacripep Unknown 0.01 % Topical

Indications

Sjogren syndrome dry eye syndrome